AU2001245803B8 - Cephalotaxine alkaloid compositions and uses thereof - Google Patents

Cephalotaxine alkaloid compositions and uses thereof Download PDF

Info

Publication number
AU2001245803B8
AU2001245803B8 AU2001245803A AU2001245803A AU2001245803B8 AU 2001245803 B8 AU2001245803 B8 AU 2001245803B8 AU 2001245803 A AU2001245803 A AU 2001245803A AU 2001245803 A AU2001245803 A AU 2001245803A AU 2001245803 B8 AU2001245803 B8 AU 2001245803B8
Authority
AU
Australia
Prior art keywords
cephalotaxine
homoharringtonine
antiproliferative agent
agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001245803A
Other languages
English (en)
Other versions
AU2001245803B2 (en
AU2001245803A1 (en
Inventor
Dennis M. Brown
Shawnya J. Michaels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of AU2001245803A1 publication Critical patent/AU2001245803A1/en
Publication of AU2001245803B2 publication Critical patent/AU2001245803B2/en
Application granted granted Critical
Publication of AU2001245803B8 publication Critical patent/AU2001245803B8/en
Assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARMACEUTICALS INTERNATIONAL GMBH Request to Amend Deed and Register Assignors: CHEMGENEX PHARMACEUTICALS INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001245803A 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof Ceased AU2001245803B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18969900P 2000-03-15 2000-03-15
US60/189,699 2000-03-15
PCT/US2001/008480 WO2001068098A2 (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid combination compositions and uses thereof

Publications (3)

Publication Number Publication Date
AU2001245803A1 AU2001245803A1 (en) 2001-12-06
AU2001245803B2 AU2001245803B2 (en) 2005-12-15
AU2001245803B8 true AU2001245803B8 (en) 2006-02-02

Family

ID=22698410

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001245803A Ceased AU2001245803B8 (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof
AU4580301A Pending AU4580301A (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU4580301A Pending AU4580301A (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid compositions and uses thereof

Country Status (11)

Country Link
US (4) US6734178B2 (enExample)
EP (1) EP1263440B1 (enExample)
JP (1) JP4929436B2 (enExample)
AT (1) ATE330611T1 (enExample)
AU (2) AU2001245803B8 (enExample)
CA (1) CA2402710A1 (enExample)
DE (1) DE60120928T2 (enExample)
DK (1) DK1263440T3 (enExample)
ES (1) ES2267741T3 (enExample)
PT (1) PT1263440E (enExample)
WO (1) WO2001068098A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
JP2003530431A (ja) 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
EP1330242A2 (en) * 2000-10-31 2003-07-30 Chemgenex Therapeutics Inc. Antiproliferative colchicine compositions and uses thereof
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
WO2004009092A1 (en) * 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) * 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
CN100396286C (zh) * 2002-12-30 2008-06-25 北京大学第一医院 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用
EP1765341A4 (en) * 2004-06-04 2010-04-14 Chemgenex Pharmaceuticals Inc PROCESS FOR TREATING PROLIFERATIVE CELL DISEASE USING NAPHTHALIMIDE AND PARP-1 INHIBITORS
WO2006086693A2 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms
WO2009148654A2 (en) * 2008-03-03 2009-12-10 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
CN118217301B (zh) * 2024-03-28 2025-08-05 宁波大学附属人民医院 一种协同治疗aml的含有8-氯腺苷和高三尖杉酯碱的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4675318A (en) * 1985-05-28 1987-06-23 Yaguang Liu Safe antileukemia drug, SAL
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
JP2003530431A (ja) * 2000-04-12 2003-10-14 ケムジェネックス・セラピューティクス・インコーポレイテッド ナフタルイミドおよび抗増殖性剤を含有する組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Khang et al Asia Pacific J Pharmacology 1992 7 pp191 - 195 *
Laster Jnr, W R et al Proc. Amer. Assn for Cancer Research 1982 23 Abstract no 786 *
Visani, C et al Leukemia 1997 11 pp624 - 628 *
Yuzhu, Z et al Chinese Journal of Clinical Oncology 1998 25 (10) pp758 - 759 *

Also Published As

Publication number Publication date
EP1263440A2 (en) 2002-12-11
US20120207855A1 (en) 2012-08-16
HK1052138A1 (en) 2003-09-05
ATE330611T1 (de) 2006-07-15
AU2001245803B2 (en) 2005-12-15
EP1263440B1 (en) 2006-06-21
DE60120928D1 (de) 2006-08-03
US20020032190A1 (en) 2002-03-14
WO2001068098A3 (en) 2002-06-06
US6734178B2 (en) 2004-05-11
JP4929436B2 (ja) 2012-05-09
US20040185117A1 (en) 2004-09-23
AU4580301A (en) 2001-09-24
CA2402710A1 (en) 2001-09-20
PT1263440E (pt) 2006-11-30
ES2267741T3 (es) 2007-03-16
US20110008307A1 (en) 2011-01-13
DE60120928T2 (de) 2007-02-08
JP2003526667A (ja) 2003-09-09
WO2001068098A2 (en) 2001-09-20
DK1263440T3 (da) 2006-10-23

Similar Documents

Publication Publication Date Title
US20120207855A1 (en) Cephalotaxine alkaloid compositions and uses thereof
EP1274458B1 (en) Compositions containing a naphthalmide and an antiproliferative agent
AU2001245803A1 (en) Cephalotaxine alkaloid compositions and uses thereof
AU2022267389A1 (en) Dosing regimens of peptide conjugates of topoisomerase i inhibitors
US20020123469A1 (en) Antiproliferative colchicine compositions and uses thereof
US20020040011A1 (en) Naphthoquinone compositions and uses thereof
US20070207977A1 (en) Naphthalimide compositions and uses thereof
US20050170015A1 (en) Antiproliferative colchicine compositions and uses thereof
AU2006202650B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
EP0572549B1 (en) Use of topotecan in the treatment of non-small cell lung carcinoma
AU2001253483B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
HK1052138B (en) Cephalotaxine alkaloid combination compositions and uses thereof
AU2001253483A1 (en) Compositions containing a naphthalimide and an antiproliferative agent
EP1707568B1 (en) A pharmaceutical composition for use in the treatment of ovarian cancer in a human afflicted therewith
US20060211648A1 (en) Naphthalimide compositions and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 19, NO 49, PAGE(S) 3841 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME CHEMGENEX THERAPEUTICS, INC., APPLICATION NO. 2001245803, UNDER INID (71) CORRECT THE NAME TO READ CHEMGENEX PHARMACEUTICALS INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired